APA (7th ed.) Citation

Nesline, M. K., Knight, T., Colman, S., & Patel, K. (2020). Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice. Clinical Therapeutics, 42(9), 1682. https://doi.org/10.1016/j.clinthera.2020.06.018

Chicago Style (17th ed.) Citation

Nesline, Mary K., Tyler Knight, Sam Colman, and Kayshap Patel. "Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice." Clinical Therapeutics 42, no. 9 (2020): 1682. https://doi.org/10.1016/j.clinthera.2020.06.018.

MLA (9th ed.) Citation

Nesline, Mary K., et al. "Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice." Clinical Therapeutics, vol. 42, no. 9, 2020, p. 1682, https://doi.org/10.1016/j.clinthera.2020.06.018.